



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/695,077	10/28/2003	Thomas Trieselmann	1/1408	4172

28501 7590 06/24/2005

MICHAEL P. MORRIS
BOEHRINGER INGELHEIM CORPORATION
900 RIDGEBURY ROAD
P. O. BOX 368
RIDGEFIELD, CT 06877-0368

EXAMINER

STOCKTON, LAURA

ART UNIT PAPER NUMBER

1626

DATE MAILED: 06/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/695,077

Applicant(s)

TRIESELMANN ET AL.

Examiner

Laura L. Stockton, Ph.D.

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-13 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-13 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____ | 6) <input type="checkbox"/> Other: ____ |

Art Unit: 1626

DETAILED ACTION

Claims 1-13 are pending in the application.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-8, 11 and 12, drawn to products of formula (I) wherein R^6 is a R^{25} and R^{26} substituted imidazole, classified in class 548, subclass 311.1+.
- II. Claims 1-5, 7, 8, 11 and 12, drawn to products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted 1,2,4-triazole, classified in class 548, subclass 262.2+.
- III. Claims 1-5, 7, 8, 11 and 12, drawn to products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted pyrrole, classified in class 548, subclass 517+.

Art Unit: 1626

- IV. Claims 1-4, 7, 8, 11 and 12, drawn to products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted pyrazole, classified in class 548, subclass 364.1+.
- V. Claims 1-4, 7, 8, 11 and 12, drawn to products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted thiomorpholine, classified in class 544, subclass 59+.
- VI. Claims 1-4, 7, 8, 11 and 12, drawn to products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted morpholine, classified in class 544, subclass 106+.
- VII. Claims 1-4, 7, 8, 11 and 12, drawn to products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted piperazine, classified in class 544, subclass 336+.
- VIII. Claims 1-4, 7, 8, 11 and 12, drawn to products of formula (I) not embraced by Groups I-VII, classified in various classes.

Art Unit: 1626

- IX. Claims 9 and 10, drawn to methods of use by administering products of formula (I) wherein R^6 is a R^{25} and R^{26} substituted imidazole, classified in class 514, subclass 396+.
- X. Claims 9 and 10, drawn to methods of use by administering products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted 1,2,4-triazole, classified in class 514, subclass 383+.
- XI. Claims 9 and 10, drawn to methods of use by administering products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted pyrrole, classified in class 514, subclass 422+.
- XII. Claims 9 and 10, drawn to methods of use by administering products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted pyrazole, classified in class 514, subclass 406+.
- XIII. Claims 9 and 10, drawn to methods of use by administering to products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted

Art Unit: 1626

thiomorpholine, classified in class 514,
subclass 227.5+.

XIV. Claims 9 and 10, drawn to methods of use by
administering products of formula (I) wherein
 R^6 is a R^{27} and R^{28} substituted morpholine,
classified in class 514, subclass 231.2+.

XV. Claims 9 and 10, drawn to methods of use by
administering products of formula (I) wherein
 R^6 is a R^{27} and R^{28} substituted piperazine,
classified in class 514, subclass 252.1+.

XVI. Claims 9 and 10, drawn to methods of use by
administering products of formula (I) not
embraced by Groups IX-XV, classified in class
514, various subclasses.

XVII. Claim 13, drawn to process of making products
of formula (I) wherein R^6 is a R^{25} and R^{26}
substituted imidazole, classified in class 548,
subclass 311.1+.

Art Unit: 1626

- XVIII. Claim 13, drawn to process of making products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted 1,2,4-triazole, classified in class 548, subclass 262.2+.
- XIX. Claim 13, drawn to process of making products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted pyrrole, classified in class 548, subclass 517+.
- XX. Claim 13, drawn to process of making products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted pyrazole, classified in class 548, subclass 364.1+.
- XXI. Claim 13, drawn to process of making products of formula (I) wherein R^6 is a R^{27} and R^{28} substituted thiomorpholine, classified in class 544, subclass 59+.
- XXII. Claim 13, drawn to process of making products of formula (I) wherein R^6 is a R^{27} and R^{28}

Art Unit: 1626

substituted morpholine, classified in class
544, subclass 106+.

XXIII. Claim 13, drawn to process of making
products of formula (I) wherein R^6 is a R^{27} and
 R^{28} substituted piperazine, classified in class
544, subclass 336+.

XXIV. Claim 13, drawn to process of making
products of formula (I) not embraced by Groups
XVII-XXIII, classified in various classes.

The inventions are distinct, each from the other
because of the following reasons: the compounds of
Groups I-VIII differ materially in structure and
element so much so as to be patentably distinct. In
addition, a reference which anticipates one group may
not even render obvious the other.

Inventions of Groups I-VIII and Groups IX-XVI are
related as product and process of use. The inventions
can be shown to be distinct if either or both of the

Art Unit: 1626

following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the process for using the product as claimed can be practiced with another materially different product.

Inventions of Groups I-VIII and Groups XVII-XXIV are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the process as claimed can be used to make other and materially different products.

Art Unit: 1626

Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and the search required for Group I, for example, is not required for Group II, restriction for examination purposes as indicated is proper. Therefore, it would impose an undue burden on the Examiner and the Patent Office's resources to examine the instant application if unrestricted.

The above groups themselves are inclusive of patentably distinct subject matter. Accordingly, along with the election of one of the above groups, the following action is also taken.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species (e.g., Example number, page number and structural depiction) from whichever group

Art Unit: 1626

is ultimately elected, even though this requirement is traversed.

Additionally, if one of the method of use groups is elected (i.e., one of Groups IX-XVI), an election of a single disclosed method of use is required (see page 44). For example:

a) A method for the treatment or prevention of atherosclerosis; or

b) A method for the treatment or prevention of Crohn's disease; or

c) A method for the treatment or prevention of diabetes; or etc.

Art Unit: 1626

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Upon the election of a single disclosed species (e.g. Example, page number and structural depiction), a scope of the elected invention that has been examined, inclusive of the elected species, will be identified by the Examiner for examination.

Art Unit: 1626

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the

Art Unit: 1626

limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims

Art Unit: 1626

may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**


Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Art Unit: 1626

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura L. Stockton whose telephone number is (571) 272-0710. The examiner can normally be reached on Monday-Friday from 6:15 am to 2:45 pm. If the examiner is out of the Office, the examiner's supervisor, Joseph McKane, can be reached on (571) 272-0699.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The Official fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

A handwritten signature in black ink, appearing to read "Laura L. Stockton", written over a horizontal line.

Laura L. Stockton, Ph.D.

Patent Examiner

Art Unit 1626, Group 1620

Technology Center 1600

June 22, 2005